This page shows what was measured, who it was measured in, and what that does not settle.
What Paricalcitol does in the body
Vitamin D and paricalcitol have been shown to reduce parathyroid hormone levels by inhibiting PTH synthesis and secretion.
From the FDA-approved label: Paricalcitol is a synthetic, biologically active vitamin D 2 analog of calcitriol. Preclinical and in vitro studies have demonstrated that paricalcitol's biological actions are mediated through binding of the VDR, which results in the selective activation of vitamin D responsive pathways.
Why people take it. 1.1 Chronic Kidney Disease Stages 3 and 4 Paricalcitol Capsules are indicated in adults for the prevention and treatment of secondary hyperparathyroidism associated with Chronic Kidney Disease (CKD) Stages 3 and 4.
What happened in people
RNAWiki has not yet published a reviewed conclusion for this use.
§ A fixed RNAWiki sentence
Where this came from
Wording RNAWiki always uses, not a finding about this substance.
No reviewed claim names a result for any goal on this record.
No source is stored against this line.
The limit that matters most
Not recorded.
Where it acts
Not recorded.
Kind of result
No result is published, so no kind of result applies yet
Supervision
RNAWiki has not recorded a supervision or regulatory status for this substance.
What the registries record it as
The substance registry classes this as chemical.
FDA substance registry · 6702D36OG5 · read 2026-08-29
Its recorded molecular formula is C27H44O3, weighing 416.64.
US prescribing information · f593b575-7537-4531-87fc-c1b0814fd018 · read 2026-08-30
Where each sentence above came from
A person wrote this explanation into the record, with the studies named in the path below.
The use the label states, quoted from it. It is written for a clinician, not for a reader without medical training.
No statement of the main limit is recorded.
The four opening statements run to 107 words.
Words this page uses
Four words worth knowing first
Chosen from what this page shows, with each one explained before the word it depends on.
Biomarker
A biomarker is a number from a test that stands in for something about health.
A picture of it, and where the picture fails
A biomarker is like a fuel gauge.
Where that stops being true. A gauge is wired to the tank. Many biomarkers are only loosely tied to health.
What people get wrong. A better number is read as a better life. Several medicines improved a number and helped nobody.
A measurable indicator used as a substitute for a clinical outcome of interest.
Placebo
A placebo is a dummy treatment given so the real one can be compared with it.
A picture of it, and where the picture fails
A placebo is like a blank control in an experiment.
Where that stops being true. A blank does nothing. People given a placebo often do get better.
What people get wrong. A placebo effect is read as imaginary. The improvement is measured and real.
An inactive intervention matched in appearance to the test intervention, used to control for non-specific effects.
Comparator
A comparator is whatever the treatment was measured against.
A picture of it, and where the picture fails
It is like the other runner in a race.
Where that stops being true. A race has one winner. A study can show both arms improved.
What people get wrong. Results are read without asking what the other group got. Beating nothing is not beating a treatment.
The control condition against which the experimental intervention is assessed.
What happened in people◇Read from sources, not yet reviewed
What happened in people
Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.
Time to Death
✗ The study did not show it
Who was studied
NCT00062699
How many people
2200
Study design
Phase 4
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Intravenous
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Percent Change From Baseline in Mean PTH During Efficacy Assessment Phase (EAP)
✗ The study did not show it
Who was studied
NCT01181531
How many people
312
Study design
Phase 4
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Intravenous
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Number of Participants in the Intent to Treat Population With a Mean Reduction in Plasma Intact Parathyroid Hormone (iPTH) of >/= 30% From Baseline Values at End of Treatment (EOT)
✗ The study did not show it
Who was studied
NCT02282813
How many people
298
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Intravenous
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Vital status
✗ The study did not show it
Who was studied
NCT01457001
How many people
284
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Intravenous
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Change From Baseline to the Last On-treatment Measurement in Urine Albumin to Creatinine Ratio (UACR) Levels Determined From the First Morning Void (FMV) Urine Collections Comparing Placebo to the Combined Paricalcitol Treatment Groups (1 Mcg and 2 Mcg).
✗ The study did not show it
Who was studied
NCT00421733
How many people
281
Study design
Phase 2
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Intravenous
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Changes in renal function with proteinuria
✗ The study did not show it
Who was studied
NCT01673204
How many people
276
Study design
Phase 4
Compared against
Not recorded for this study
Kind of result
What a body can do day to day
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Intravenous
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
What we know
RNAWiki holds 6 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.
What is missing or unclear◇Read from sources, not yet reviewed
Were people like you studied?
RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.
Who was studied
People similar to this profile were included.
& USAGE 1.1 Chronic Kidney Disease Stages 3 and 4 Paricalcitol Capsules are indicated in adults for the prevention and treatment of secondary hyperparathyroidism associated with Chronic Kidney Disease (CKD) Stages 3 and 4. Pediatric use information for patients 10 to 16 years of age is approved for AbbVie Inc.’s Zemplar (Paricalcitol) capsules.
Who is missing from the studies
Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What the label states about particular groups
On pediatric, the label states: “Safety and effectiveness of Paricalcitol Capsules in pediatric patients under the age of 10 years have not been established.”
US prescribing information · f593b575-7537-4531-87fc-c1b0814fd018 · read 2026-08-30
On older people, the label states: “Of the total number (n = 220) of CKD Stages 3 and 4 patients in clinical studies of Paricalcitol capsules, 49% were age 65 and over, while 17% were age 75 and over.”
US prescribing information · f593b575-7537-4531-87fc-c1b0814fd018 · read 2026-08-30
On people who are pregnant, the label states: “Risk Summary Limited data with Paricalcitol capsules in pregnant women are insufficient to inform a drug- associated risk for major birth defects and miscarriage.”
US prescribing information · f593b575-7537-4531-87fc-c1b0814fd018 · read 2026-08-30
On people who are breastfeeding, the label states: “Risk Summary There is no information available on the presence of paricalcitol in human milk, the effects of the drug on the breastfed infant or the effects of the drug on milk production.”
US prescribing information · f593b575-7537-4531-87fc-c1b0814fd018 · read 2026-08-30
Where the result stopped carrying
This is a scope explorer, not a diagnosis engine.
It shows who was studied so you can see whether people similar to you were included.
RNAWiki cannot tell whether a study fits you. It can show who was in it.
What it would be like to take◇Read from sources, not yet reviewed
Why it might seem to do nothing
A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.
It was studied in different people
The people in the studies were not much like the reader.
On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
The evidence may simply be wrong
Small early studies often do not hold up.
On this record: RNAWiki has not yet published a reviewed conclusion for this use.
Other reasons RNAWiki checked and found nothing for (11)
It was studied for a different goal
The studies measured something else entirely. Nothing in this record points to this reason.
A different form was studied
The studied form is not the form on the shelf. Nothing in this record points to this reason.
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.
None of these is a reason to take more. Taking more is not a step this page ever suggests.
What it would be like to take◇Read from sources, not yet reviewed
What taking it involves
The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.
How it is supplied
Given by a clinician
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Read from the recorded approval status.
No source is stored against this line.
Form and route
Intravenous
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form and route recorded on this substance.
No source is stored against this line.
Who oversees it
RNAWiki has not recorded a supervision or regulatory status for this substance.
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
No register row and no identity class settled the question.
No source is stored against this line.
What is in the pack
Sold as solution, capsule, injectable, injection, solution, given by the intravenous, oral, injection route.
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
Recorded notes on how this is sold and what that means for what is in the pack.
No source is stored against this line.
Where it is registered
Regulatory records are listed in the technical disclosure at the foot of this page.
# Counted from records
Where this came from
A count of rows RNAWiki holds. It describes our records, not your body.
Register entries are stored per jurisdiction and shown with their dates.
No source is stored against this line.
Why people stop
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No record of why people stopped taking it is stored for this substance.
No source is stored against this line.
What it would be like to take∅Nothing found in the sources checked
What can go wrong
Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.
∅Nothing found in the sources checked
No harm is recorded against this substance in the sources RNAWiki checked. Finding nothing is not the same as showing there is nothing.
The sources listed were searched and held nothing. That is not the same as nothing existing.
Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.
Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What is missing or unclear◇Read from sources, not yet reviewed
Does the exact form matter?
Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.
The form that was studied
Intravenous
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form used in the studies cited on this page.
No source is stored against this line.
What is sold
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
Nothing further is recorded about which forms are sold.
No source is stored against this line.
What is recorded as being sold
53 products list this as an active ingredient in the United States drug directory. 53 of them contain it and nothing else.
FDA National Drug Code directory · 0074-4637 · read 2026-08-29
They are sold as capsule, capsule, liquid filled, injection, injection, solution and powder, taken intravenous and oral.
FDA National Drug Code directory · 0074-4637 · read 2026-08-29
The regulator's established pharmacologic class for it is cholecalciferol [cs], ergocalciferols [cs] and vitamin d analog [epc].
FDA National Drug Code directory · 0074-4637 · read 2026-08-29
16 published labels name it as an active ingredient. 16 of them describe this substance alone, which is where its own label text on this page comes from.
US prescribing information · f593b575-7537-4531-87fc-c1b0814fd018 · read 2026-08-29
Those labels are classed as human prescription drug.
US prescribing information · f593b575-7537-4531-87fc-c1b0814fd018 · read 2026-08-29
Paricalcitol is oral at 3 DOSAGE FORMS & STRENGTHS Paricalcitol Capsules are available as 1 mcg, 2 mcg, and 4 mcg soft gelatin capsules. 1 mcg-grey colour oval shaped soft gelatin capsules imprinted with "12" in black ink. 2 mcg-brown colour o…, recorded as fda label in effect 2022-12-02 in the United States.
US prescribing information · f593b575-7537-4531-87fc-c1b0814fd018 · read 2026-08-30
Recorded price in US: 1.23635–2.64844 USD per one unit as the pricing file counts it — a tablet, capsule, patch or single item, across 6 priced products whose strengths and pack forms differ, as of 2026-08-26, paid by retail pharmacies buying the product, as surveyed by the Centers for Medicare & Medicaid Services. It is not a list price, an insurance price, or what anyone pays at a counter..
Recorded source · 2026-08-26 · read 2026-08-28
Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.
What it would be like to take◇Read from sources, not yet reviewed
What you could measure
This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.
RNAWiki could not confidently classify this substance, so no self-experiment plan is offered.
Questions worth asking
Which of the trials of Paricalcitol studied people like me?
What was measured, and for how long?
Was the result a laboratory value or a health outcome?
What would we watch for, and when would we stop?
Tracking can show whether something changed for you. It cannot show what caused it.
RNAWiki records evidence. It does not say whether this substance is right for you.
What is missing or unclear◇Read from sources, not yet reviewed
What nobody knows yet
Open questions, each with why it is open and what would close it.
Missing populations
Which groups were under-represented in the studies has not been recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing long-term data
No completed tested study window is recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
No reviewed conclusion
RNAWiki has not yet published a reviewed conclusion for this use.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing interaction studies
No interaction was found in the registers checked. Not finding one is not the same as showing there is none.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Formulation uncertainty
Several salts, forms or products of Paricalcitol are recorded. Results from one form may not transfer to another.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Mechanism not reviewed
No reviewed mechanism story exists for this substance.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
What happened in people◇Read from sources, not yet reviewed
Check any of this yourself
Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.
How many documents were read
16 documents were read for this substance.
RNAWiki source record
11 of them state the same tMax, and they agree.
RNAWiki source record
16 of them state the same proteinBinding, and they agree.
RNAWiki source record
5 of them state the same volumeOfDistribution, and they agree.
RNAWiki source record
Where else this substance is registered
FDA substance identifier (UNII)
6702D36OG5
RxNorm concept
577315
Checks this page had to pass
✓ Passed
Identity resolved
no open identity hold
✓ Passed
No unresolved merge across substance families
no quarantine open
✓ Passed
Every public sentence names a source
The opening statement carries the origin: Written into the record, not signed off.
✗ Not passed
Trial roles classified for highlighted evidence
No registered study is classified as testing this substance.
✓ Passed
No internal keys in reader text
enforced by the copy-contract test over the rendered page
✗ Not passed
Safety mode resolved
No register row and no identity class settled the question.
✓ Passed
Canonical metadata present
slug and display name present
What is missing or unclear◇Read from sources, not yet reviewed
How this medicine reached us
Kept near the foot of the page. A historical event moves up only when it changes something about this substance today.
What the approval register records
20 approved applications cover products containing this substance. The earliest was NDA020819, approved 19980417 to ABBVIE.
This order is fixed in code and does not count clicks or time on the page.
What is not here
9 questions this page could not answer
These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.
What was measured, goal by goal — found nothing in the sources checked.
How close this is to real life — found nothing in the sources checked.
The path through the body — found nothing in the sources checked.
Felt, measured, or meaningful — found nothing in the sources checked.
How long anything takes — found nothing in the sources checked.
What it may clash with — found nothing in the sources checked.
Other ways to the same goal — found nothing in the sources checked.
Claims that go past the evidence — found nothing in the sources checked.
What changed on this page — found nothing in the sources checked.
The record as stored
The full record, for auditing
Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.
Recorded evidence blocks (11)
Q1
On the Paricalcitol label: indicated for what?
"Paricalcitol injection is indicated for the prevention and treatment of secondary hyperparathyroidism in patients 5 years of age and older with chronic kidney disease (CKD) on dialysis. Paricalcitol injection is a vitamin D analog indicated for the prevention and treatment of secondary hyperparathyroidism in patients…": indications and usage on Paricalcitol's label. DailyMed label · 6937c596-9ca4-480e-9090-b9d8a3c271c8 · 2025-10-23
Q2
97 registered trials of Paricalcitol — at which phases?
Registered studies posting no result
57 of 97
97 registered studies of Paricalcitol: 27 phase4, 23 phase2, 22 phase3, 11 na, 10 phase1, 3 na or unstated, 2 early phase1. CLINICALTRIALS_SNAPSHOT · 2026-09-01
118 with a PubMed record
Show the evidence
phase4
27
phase2
23
phase3
22
na
11
phase1
10
na or unstated
3
8 more recorded rows
early phase1
2
completed
72
terminated
16
unknown
3
withdrawn
3
active not recruiting
1
not yet recruiting
1
recruiting
1
recorded 2026-09-01 · last checked 2026-09-04
Q3
18 of Paricalcitol's trials stopped: futility/efficacy, accrual/recruitment, funding/business, other?
futility/efficacy (2), accrual/recruitment (6), funding/business (4) and other (6): Paricalcitol's stop wording, clustered. CLINICALTRIALS_SNAPSHOT · 2026-09-01
"Withdrawn due to low accrual"; 18 of 97 registered studies
Show the evidence
Trial
NCT00258258
terminated; "Withdrawn due to low accrual"
NCT00469599
terminated; "Terminated after 86 pt included, because of recruitment problems"
NCT00469625
withdrawn; "Investigator left the Institution."
NCT00599963
withdrawn; "Funding problem."
NCT00616902
terminated; "This study was prematurely terminated due to low enrollment"
NCT00634582
terminated; "slow accrual"
12 further recorded trials
NCT00664430
terminated; "Low enrollment rate"
NCT01012414
terminated; "Futility in enrollment as of May 31, 2011"
NCT01134315
terminated; "Terminated after FDA agreement."
NCT01197664
terminated; "Study terminated due to funding issues"
NCT01630408
withdrawn; "Investigator decided not to pursue."
NCT01725113
terminated; "Nationwide shortage of study meds in 2013 loss of funding \& competing studies"
NCT02372695
terminated; "Protocol showed to be inappropriate for the evaluation of the selected patients"
NCT02876211
terminated; "Difficult inclusion of patients diagnosed with renal anemia in chronic hemodialysis patients without hyperparathyroidism."
NCT03300921
terminated; "Newer research suggested that paricalcitol may be harmful to a subset of pancreatic cancer patients and it is not feasible to subtype patients in the short time frame before surgery"
NCT03519308
terminated; "The accrual goal could not be met and the drug manufacturer pulled support"
NCT03520790
terminated; "Phase II was not pursued due to futility based on the results of the NAPOLI-3 therapeutic clinical trial."
NCT04064827
terminated; "Company Decision"
recorded 2026-09-01 · last checked 2026-09-04
Q4
Human studies of Paricalcitol used paricalcitol (initial dose 1 mcg orally per day) — over how long?
Human studies of Paricalcitol used "paricalcitol (initial dose 1 mcg orally per day)". ClinicalTrials.gov · 2026-09-01
5 recorded entries; human; orally, injection, oral; also "paricalcitol injection 4 mcg/mL", "Vitamin D 2mg daily for 2 weeks oral paricalcitol", "Paricalcitol Capsules, 4 mcg"
Show the evidence
human
NCT00469625
orally; paricalcitol (initial dose 1 mcg orally per day)
NCT00616902
injection; paricalcitol injection 4 mcg/mL
NCT02018133
oral; Vitamin D 2mg daily for 2 weeks oral paricalcitol
NCT02322632
Paricalcitol Capsules, 4 mcg
NCT02372695
Zemplar- 1 ug/day
recorded 2026-09-01 · last checked 2026-09-04
Q5
Paricalcitol's half-life is 15.4 hours — which schedules were studied?
15.4 hours, the half-life Paricalcitol's label states: "The mean elimination half-life of paricalcitol after administration of 0.24 mcg/kg paricalcitol IV bolus dose in CKD HD and PD patients is 13.9 and 15.4 hours, respectively (Table 5)." DailyMed label · 6937c596-9ca4-480e-9090-b9d8a3c271c8 · 2025-10-23
Show the evidence
half lifepharmacokinetics
15.4 hours; The mean elimination half-life of paricalcitol after administration of 0.24 mcg/kg paricalcitol IV bolus dose in CKD HD and PD patients is 13.9 and 15.4 hours, respectively (Table 5).
metabolismpharmacokinetics
Elimination Metabolism After intravenous administration of a 0.48 mcg/kg dose of 3 H-paricalcitol, parent drug was extensively metabolized, with only about 2% of the dose eliminated unchanged in the feces and no parent drug found in the urine.
recorded 2025-10-23 · last checked 2026-09-04
Q6
Which running trial of Paricalcitol could settle lifespan?
NCT06209268 measures survival (days), reading out 2026-02-01.
1 open trial; n 90; "The Impact of Selective Vitamin D Receptor Activation on Clinical Outcomes in Septic Patients"
Show the evidence
TrialNCT06209268
"The Impact of Selective Vitamin D Receptor Activation on Clinical Outcomes in Septic Patients"; n 90; "survival (days)"; 2026-02-01
Q7
Which 29 trials of Paricalcitol posted no result?
Posted no result
29 of 29 completed trials
Registrations
NCT00307840, NCT00064376, NCT00454350, NCT00686751, NCT00463021 and NCT00294866, and 23 more
Completion dates
oldest 2005-07; newest 2023-01-03
Show the evidence
Trial
NCT00307840
2005-07
NCT00064376
2005-11
NCT00454350
2007-07
NCT00686751
2007-09
NCT00463021
2007-12
NCT00294866
2008-01
14 further recorded trials
NCT00800358
2009-12
NCT00656032
2010-01
NCT00958451
2011-01
NCT02322632
2011-02
NCT00796679
2011-06
NCT01136564
2011-12
NCT01331317
2012-04
NCT02018133
2012-06
NCT01768351
2012-10
NCT01220050
2013-02
NCT00637897
2013-03
NCT01204528
2013-07
NCT02090608
2013-12
NCT01820767
2014-03
Q8
At the median, Paricalcitol's trials enrolled 41 people — anything larger?
Median enrolment
41
Largest enrolment
2200
Registered trials counted
95
Q9
What do 282 spontaneous reports say about Paricalcitol — and not say?
These are reports people sent to a regulator. They do not show the medicine caused the reaction. Nobody counted how many people took the medicine and reported nothing. The same event can be reported more than once, and many reports are incomplete. News coverage, lawsuits and new warnings change how often people report. A count is not a rate and not a risk.
Paricalcitol appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 282 reaction mentions were counted: renal transplant 58; calciphylaxis 37; hypercalcaemia 37; transplant 32. FAERS via Open Targets · CHEMBL1200622 · 2026-06-24
Show the evidence
renal transplant
58
calciphylaxis
37
hypercalcaemia
37
transplant
32
renal failure chronic
24
shunt occlusion
24
4 more recorded rows
cardiac failure
22
blood parathyroid hormone increased
16
parathyroidectomy
16
skin ulcer
16
recorded 2026-06-24 · last checked 2026-09-04
Q10
Which 10 reactions does Paricalcitol's label not list?
Strong CYP3A Inhibitors Clinical Impact Paricalcitol is partially metabolized by CYP3A.
drug_interactions
Exposure of paricalcitol will increase upon coadministration with strong CYP3A inhibitors [see Clinical Pharmacology (12.3) ].
drug_interactions
Examples Boceprevir, clarithromycin, conivaptan, grapefruit juice, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, mibefradil, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telithromycin, and voriconazole Intervention If a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor, dose adjustment of paricalcitol may be necessary.
In vitro data suggest that paricalcitol is metabolized by multiple hepatic and non-hepatic enzymes, including mitochondrial CYP24, as well as CYP3A4 and UGT1A4.
pharmacokinetics
Drug Interaction Studies An in vitro study indicates that paricalcitol is not an inhibitor of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A at concentrations up to 50 nM (21 ng/mL) (approximately 20-fold greater than that obtained after highest tested dose).
2 more recorded rows
Interaction statementpharmacokinetics
In fresh primary cultured hepatocytes, the induction observed at paricalcitol concentrations up to 50 nM was less than two-fold for CYP2B6, CYP2C9 or CYP3A, where the positive controls rendered a six- to nineteen-fold induction.
Interaction statementpharmacokinetics
Strong CYP3A Inhibitors Ketoconazole The effect of multiple doses of ketoconazole, a strong inhibitor of CYP3A administered as 200 mg BID for 5 days, on the pharmacokinetics of paricalcitol capsule has been studied in healthy subjects.
ChEMBL 37 — CC BY-SA 3.0 Unported · ChEMBL ATC CC BY-SA · ClinicalTrials.gov — US Government work · Open Targets 26.06 — CC0 · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work
✗ required summary fields resolved: 4 required field(s) not terminal: Why people use it, Best-supported result, Biggest unanswered question, Human evidence
✓ public claims reviewed: 0 reviewed claim(s); drafts are never rendered
✓ source coverage passed: 6 source rows
✓ no critical contamination: no quarantine open
✓ canonical metadata passed: slug and display name present
✓ no raw internal fields: enforced by the copy-contract test over the rendered page
This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.